SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables of -$222K in Q1 FY2026
Q1 FY2026 accounts receivables was -$222K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (8K) USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8K) | — |
Accounts Receivables vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $89.24M USD | +37.3% | +15.9% | 1.7% | |
| LTM Jun 2026 | $60.95M USD | +79.6% | +156.6% | 9.9% | |
| LTM Apr 2026 | $42.26M USD | -270.2% | — | 14.6% | |
| LTM Sep 2026 | $34.89M USD | -77.2% | -7.7% | 0.3% | |
| LTM Mar 2026 | $19.05M USD | -355.9% | +58.8% | 250.2% | |
| LTM Mar 2026 | $8.52M USD | +190.0% | — | 6.7% | |
| LTM Mar 2026 | $1.14M USD | -118.2% | — | 1.4% | |
| LTM Mar 2026 | $874K USD | -34.0% | — | 1.7% | |
| LTM Mar 2026 | CHF 272.05K CHF | -142.6% | — | 54.0% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $8K USD | — | — | — |
| Peer median (excluding SGP) | — | -77.2% | +37.4% | 6.7% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.